Almost 50 caregivers and family members of hereditary transthyretin amyloidosis (hATTR) patients have responded to ARC's 'hATTR treatment perspectives' survey so far, with responses from across the United States and across the globe.
The information caregivers have been sharing with us about the impact of hATTR on their own lives and what they think is important about treating the disease is incredibly valuable and will help us achieve our goals to improve access to new treatments for hATTR. Thank you to everyone who has taken part! However, we need to hear more people's voices so that we can make the most significant impact.
If you are a caregiver or family member of a hATTR patient and have not yet taken part in the survey please consider doing so. The survey will remain open until June 14th. Take the survey today!
Please note this survey is for caregivers of hATTR patients only. We are asking for hATTR patients' views in a separate survey, which you can find here.
If you are a caregiver of a patient with AL, wild-type of other type of amyloidosis please keep an eye on our website for future surveys asking for your views.